North America

Drug industry cash influences how doctors treat their patients.

The change could cut reimbursement for some of the best-selling drugs in America, in half, or more.

From 2012 to 2018, the federal health care program spent $39.7 billion — adjusted for inflation and discounts — on inhalers to help plan beneficiaries combat asthma and chronic obstructive pulmonary disease, or COPD

Former U.S. Presidents Barack Obama, George W. Bush and Bill Clinton said they were willing to be vaccinated against the novel coronavirus on television in order to ease any public skepticism over the safety of new vaccines.

The contracts are complicated and full of risks for drug companies. But there's also a risk to steering clear of the arrangements -- reduced or restricted access to a company's medication.

Gilead’s remdesivir is overpriced at $3,000, group says.

More than $2 billion a year was paid by pharma companies to doctors, fueling an increase in prescriptions.

The proposal, first described in an Advance Notice of Proposed Rulemaking (ANPRM) issued in 2018, was a primary focus of President Trump’s American Patients First Drug Pricing Blueprint and most recent Drug Pricing Executive Order.

NBC News’ Dr. John Torres breaks down what to expect from a potential approval of the Covid-19 vaccine in the U.S. now that the U.K. has given their approval.

White House press secretary Kayleigh McEnany says it is a "tremendous achievement" for the U.S. to have as many as 40 million vaccine doses ready by year’s end, crediting the accomplishment to President Donald Trump's background in the business world.

A new study shows that launch prices of drugs in the United States have more than doubled since a 2005 Medicare policy change.

A Step in the Right Direction

Planned changes to the guidelines of Canada’s Patented Medicine Prices Review Board (PMPRB) could make vital treatments harder to get, says a Calgary woman living with a rare blood disorder.

The pharmaceutical industry raises prices because they can. Over the past decade, almost every new medication brought to market was paid for with a healthy investment of taxpayer dollars.

No matter how wonderful single-payer health care might be in other respects, it wouldn’t reduce U.S. health-care spending to European levels.